Labsco will be an exclusive sales agent partner for the FilmArray system in certain market segments in the US.
Personalized medicines haven't been a big part of APMs to date, but the report suggests ways in which payment models might be structured to spur utilization.
The tests combine the company's second-generation proteomic ovarian cancer test OVA2 with patient ultrasound results and symptom data.
Researchers have created panels for ovarian hyperstimulation syndrome and to detect mutations in BCR-ABL1 gene fusions.
Having just wrapped up a key clinical trial of its first sepsis assay in around 200 ICU patients, the firm hopes to gain US marketing clearance by the end of this year.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.